回眸血液透析要點(diǎn)(編輯修改稿)
2024-10-03 23:38 本頁面
【文章內(nèi)容簡介】 ous hemodialysis[J].Trans Am Soc Artif Intern Organs ,1960,6:88103. [2] Quinton W, Dillard D, Scribner BH. Cannulation of bloodvessels for prolonged hemodialysis[J]. Trans Am Soc Artif Intern Organs ,1960,6:104113. [3] Brescia MJ,Cimino JE,Appel K,et hemodialysisusing venipuncture and a surgically created arteriovenous fistula[J].N Engl J Med,1966,275:10891092. [4] Depner TA. Prescribing hemodialysis:a guide to ureamodeling[J]. Boston: Kluwer Academic, 1991. [5] Locatelli F, Manzoni C, Di Filippo S. The importance of convective transport[J].Kidney Int, 2024 (Suppl):115120. [6] Meyer TW, Hostetter TH. Uremia[J].N Engl J Med, 2024,357:13161325. [7] National Kidney Foundation. DOQI clinical practice guide lines for peritoneal dialysis adequacy[J]. Am J Kidney Dis ,1997,30: 67136. [8] Cooper BA , Branley P , Bulfone L ,et al. for the IDEAL Study : A randomized controlled trial of early versus late initiation of dialysis[J] . N Engl J Med,2024, 363:606619 . [9] Rosansky S, Glassock R, Clark William. Early start of dialysis:A critical Review[J].Clin J Am Soc Nephrol,2024,6:12221228. [10] Lowrie EG, Laird NM, Parker TF, Sargent JA. Effect of the hemodialysis prescription of patient morbidity: report from the National Cooperative Dialysis Study[J].N Engl J Med,1981,305:11761181. [11] Eknoyan G, Beck GJ, Cheung AK, et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis[J]. N Engl J Med ,2024,347:20242024. [12] Paniagua R, Amato D, Vonesh E, et al. Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized, controlled trial[J]. J Am Soc Nephrol ,2024,13:13071320. 第二十一頁，共二十七頁。 Page 22 [13] Vanholder R, Baurmeister U, Bru P,Cohen G, Glorieux G,Jankowski J. A bench to bedside view of uremic toxins[J].J Am Soc Nephrol, 2024,19:863870. [14] Hornberger JC, Chernew M, Petersen J,Garber AM. A multivariate analysis of mortality and hospital admissions with highflux dialysis[J]. J Am Soc Nephrol ,1992,3:12271237. [15] Koda Y, Nishi S, Miyazaki S, et al. Switch from conventional to highflux membrane reduces the risk of carpal tunnel syndrome and mortality of hemodialysis patients[J]. Kidney Int ,1997,52:10961101. [16] Locatelli F, Mastrangelo F, Redaelli B, et al. Effects ofdifferent membranes and dialysis technologies on patient treatment tolerance and nutritional parameters[J]. Kidney Int, 1996,50:12931302. [17] Port FK, Wolfe RA, HulbertShearon TE, et al. Mortality risk by hemodialyzer reuse practice and dialyzer membrane characteristics: results from the USRDS dialysis morbidityand mortality study[J]. Am J Kidney Dis ,2024,37:276286. [18] Held PJ, Levin NW, Bovbjerg RR, Pauly MV, Diamond and duration of hemodialysis treatment[J].JAMA, 1991,265:871875. [19] Marshall MR, Byrne BG, Kerr PG, McDonald SP. Associations of hemodialysis dose and session length with mortality risk in Australian and New Zealand patients[J].Kidney Int ,2024,69:12291236. [20] Saran R, BraggGresham JL, Levin NW, et al. Longer treatment time and slower ultrafiltration in hemodialysis:associations with r
電大資料相關(guān)推薦
鄂ICP備17016276號(hào)-1